LGVN (Longeveron) ROIC %: -347.56% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LGVN Longeveron Inc LGVN
45 GF Score
Price $0.61
GF Value $0.38
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Longeveron ROIC %?

Longeveron LGVN +1.40% 45 ROIC % is -347.56% as of Mar. 2026. GuruFocus rates LGVN with a GF Score™ of 45/100 and a GF Value™ of $0.38 (Significantly Overvalued). The stock has 6 warning signs investors should review.

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. Longeveron's annualized return on invested capital (ROIC %) for the quarter that ended in Mar. 2026 was -347.56%.

As of today (2026-07-19), Longeveron's WACC % is -3.85%. Longeveron's ROIC % is -389.97% (calculated using TTM income statement data). Longeveron earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Longeveron  (NAS:LGVN) ROIC % Explanation

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROIC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Longeveron's WACC % is -3.85%. Longeveron's ROIC % is -389.97% (calculated using TTM income statement data). Longeveron earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Longeveron ROIC % Related Terms


Longeveron ROIC % Historical Data

* Premium members only.

The historical data trend for Longeveron's ROIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Longeveron ROIC % Chart

Longeveron Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROIC %
Get a 7-Day Free Trial -215.36 -203.61 -248.42 -237.28 -384.85

Longeveron Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -321.80 -347.02 -484.79 -378.58 -347.56

LGVN vs MRKR, PLUR, VYNE: ROIC % Comparison

For the Biotechnology subindustry, Longeveron's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Longeveron ROIC % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Longeveron's ROIC % distribution charts can be found below:

* The bar in red indicates where Longeveron's ROIC % falls into.


LGVN
45GF Score
Longeveron Inc LGVN
ROIC % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Longeveron ROIC % Calculation

Longeveron's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in Dec. 2025 is calculated as:

ROIC % (A: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2024 ) + Invested Capital (A: Dec. 2025 ))/ count )
=-23.287 * ( 1 - 0% )/( (6.597 + 5.505)/ 2 )
=-23.287/6.051
=-384.85 %

where

Longeveron's annualized Return on Invested Capital (ROIC %) for the quarter that ended in Mar. 2026 is calculated as:

ROIC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=-19.1 * ( 1 - 0% )/( (5.505 + 5.486)/ 2 )
=-19.1/5.4955
=-347.56 %

where

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data. The tax rate is limited to between 0% and 100%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROIC % →
What does a ROIC % of -347.56% mean?
Longeveron (LGVN) has a ROIC % of -347.56% as of Mar. 2026. Return on invested capital is the ratio of current-period net income to average two-period invested capital. View historical data on Longeveron and its competitors.
Is Longeveron's ROIC % too high?
Longeveron's current ROIC % is -347.56%. Overall, Longeveron has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Longeveron's ROIC % compare to MRKR and PLUR?
Longeveron's ROIC % of -347.56% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROIC % for a Biotechnology company?
A good ROIC % depends on the Biotechnology industry context. However, ROIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROIC % mean?
A high ROIC % can signal that a stock is expensive relative to its fundamentals. Return on invested capital is the ratio of current-period net income to average two-period invested capital. View historical data on Longeveron and its competitors. Longeveron's current ROIC % is -347.56%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Longeveron stock overvalued right now?
Based on GuruFocus' analysis, Longeveron (LGVN) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.38, compared to a current price of $0.61 — trading 60.8% above its estimated fair value. The current ROIC % is -347.56%. Longeveron's overall GF Score™ is 45/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROIC % calculated?
ROIC % is calculated from a company's financial statements. For Longeveron (LGVN), the current ROIC % is -347.56% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Longeveron (LGVN) Overvalued in 2026?

Based on GuruFocus' analysis, Longeveron stock appears to be overvalued. The current stock price of $0.61 is trading 60.8% above its estimated GF Value™ of $0.38. GuruFocus considers Longeveron to be Significantly Overvalued.

Key valuation signals for LGVN:

  • ROIC %: -347.56%
  • GF Value™: $0.38 vs. price of $0.61 (60.8% above fair value)
  • GF Score™: 45/100 with 6 warning signs

No single metric tells the full story. See the LGVN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Longeveron Business Description

Address 1951 NW 7th Avenue, Suite 520, Miami, FL, USA, 33136
Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.
45GF Score

Get the complete analysis for LGVN

ROIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.61
Price
$0.38
GF Value